PMG 1015
Alternative Names: PMG-1015Latest Information Update: 14 Oct 2025
At a glance
- Originator Pulmongene
 - Class Antifibrotics; Monoclonal antibodies
 - Mechanism of Action MDK protein inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
 
Most Recent Events
- 17 May 2025 PMG 1015 is still in phase I trials for Idiopathic pulmonary fibrosis (IPF) (In volunteers) in Australia.
 - 17 May 2025 Adverse events and pharmacokinetics pooled analysis data from a two phase Ia trial in healthy volunteers presented 121st International Conference of the American Thoracic Society (ATS 2025) (CTR20221571)
 - 28 Nov 2024 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in Australia (Parenteral)